Role of stereotactic body radiation therapy for hepatocellular carcinoma

Table 3 Retrospective studies of stereotactic body radiation therapy for hepatocellular carcinoma and other liver tumors

Ref.	Country	Patient number	Median volume (mL)	Median size, cm	Median dose (range)/fraction, Gy	Median follow-up (range) (mo)	Local control	Overall survival
Choi et al[32], 2006	South Korea(The Catholic Univ. of Korea)	20	-	3.8 (2-6.5)	Fixed50 Gy/5 or 10 fr	23(3-55)	100%	70%(1 yr)43%(2 yr)
Zhang et al[72], 2007	China(Hebei)	27	-	< 5 cm: 18%3-5 cm: 41%> 5 cm: 41%	Median40 (32-42) Gy/5 fr	10(3-21)	22%(1 yr)	-
Choi et al[33], 2008	South Korea(The Catholic Univ. Korea)	31	25(4-57)	-	Variable33 (30-39) Gy/3 fr	11(2-19)	100%	81%(1 yr)
Louis et al[34], 2010	Belgium	25	48(7-363)	-	Fixed45 Gy/3 fr	13(1-24)	95%(1 yr)	79%(1 yr)52%(2 yr)
Kwon et al[35], 2010	South Korea(The Catholic Univ. of Korea)	42	15(3-82)	-	Variable30-39 Gy/3fr	29(8-4)	72%(1 yr)68%(3 yr)	93%(1 yr)59%(3 yr)
Seo et al[36], 2010	South Korea(Korea Inst. of Radiological and Medical Sciences)	38	41(11-464)	-	Variable33-57 Gy/3-4 fr	15(3-27)	66%(2 yr)	61%(2 yr)
Huang et al[38], 2012	Taiwan	36	-	4.4(1.1-12)	Variable37 (25-48 Gy)/4-5 fr	14(2-35)	88%(1 yr)75%(2 yr)	64%(2 yr)
Honda et al[39], 2012	Japan(Hiroshima)	30	-	1.6(1-3)	Fixed 48 Gy/4 fr or 60 Gy/8 fr	12(6-38)	100%	100%(1 yr)100%(3 yr)
Bae et al[40], 2013	South Korea(Korea Inst. of Radiological and Medical Sciences)	35	131(21-2189)	-	Variable45 (30-60) Gy/3-5 fr	14(1-44)	69%(1 yr)51%(3 yr)	52%(1 yr)21%(2 yr)
Xi et al[41], 2013	China(Sun Yat-sen Univ.)	41	65 (± 48)	-	Variable36 (30-48) Gy/6 fr	10(4-25)	95%	50%(1 yr)
Sanuki et al[43], 2013	Japan(Ofuna)	185	8(1.5-65)	-	FixedCP-A: 40 Gy/5 fr/CP-B: 35 Gy/5 fr/	24(3-80)	91%(3 yr)	70%(3 yr)

CP: Child-Pugh.